- Frontier AI models for protein and molecule design
- Strong pharma partnership track record
- Linked to DeepMind's research depth
Isomorphic Labs
DeepMind spinout for AI drug design
SF8.4
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Mine literature for research signals
Mine literature for research signals
Best for
Large pharma partners and biologics programs
Pricing
Custom
SoftFinders Score
8.4 / 10
Overview
What is Isomorphic Labs?
Isomorphic Labs is a DeepMind spinout developing AI models for drug discovery, including protein structure prediction and molecule generation for pharmaceutical and biologics partners.
- Partnership model: Engagement centers on collaborative R&D programs rather than self-serve software subscriptions, making it most relevant to organizations prepared for long-term work.
- Scientific focus: Its platform applies computational biology and frontier AI to protein and molecule design to accelerate selected discovery workflows.
- Evidence expectations: The platform does not guarantee clinical outcomes; buyers should examine data access, timelines to validated leads, and each collaboration's cost structure.
- Buying considerations: Pricing is sales-led and scoped individually, while teams should confirm workflow fit, implementation scope, and available support before committing.
For suitably resourced partners, the central question is whether its collaborative model matches the program's scientific, operational, and commercial requirements.
KEY FEATURES
What you get out of the box
Knowledge Graph
Connects biological and chemical knowledge sources
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Workflows for pharma partner collaborations
USE CASES
Where teams put it to work
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Accelerate molecule design cycles
Editorial Take
What we like, and what to verify
- Not available as self-serve software today
- Engagement relies heavily on partnership exclusivity
- Public access to platform tools is limited
Screenshots
A look inside
Alternatives
Tools to consider next
Insitro SF 8.2
Why consider it
ML drug discovery with proprietary biology data
Recursion SF 8.1
Why consider it
AI biotech with cellular imaging and automation
BenevolentAI SF 7.8
Why consider it
AI drug discovery using biomedical knowledge graphs
Abridge SF 8.8
Why consider it
Generative AI scribe for health systems
Nuance DAX Copilot SF 8.7
Why consider it
Microsoft and Nuance enterprise ambient scribe
FAQ